KCNJ10 and myeloid sarcoma: Srivastava et al., employing solid-phase ELISA with recombinant KIR4.1, initially reported a high prevalence of anti-KIR4.1 antibodies in the sera of MS patients (46.9%), whereas such reactivity was absent in healthy controls (0%) and rare in patients with other neurological diseases (0.9%) [106].